Assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) and other tumor types.
MPLN offers SP263 immunohistochemical testing for the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded tissue.PD-L1 expression level utilizing this clone has been associated with response to durvalumab (IMFINZI, AstraZeneca UK Limited).
Immunohistochemistry, Technical component (TC) available
This assay utilizes the VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody (VENTANA PD-L1 (SP263)) which is a rabbit monoclonal primary antibody directed against the programmed deathligand1 (PD-L1) B7 homolog 1 (B7-H1, CD274). The antibody detects the extracellular domain of PD-L1 and produces membranous and/or cytoplasmic staining.
Formalin fixed paraffin embedded tissue block
Bone Marrow core in formalin
Biopsy in formalin
Unstained Previously Prepared Slides (paraffin sections on slides)
Transport at ambient temperature.
In extreme hot weather, ship with a cool pack
Improper specimen labeling; Insufficient sample; Inadequate fixation and/or processing
Quantitative in Tumor Infiltrating Lymphocytes (TILs): Cut off POSITIVE in =/>25% of tumor infiltrating lymphocytes (TILs); NEGATIVE (no reactivity in tumor infiltrating lymphocytes, <25%)
PD-L1 IHC is indicated as an aid in the assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) and other tumor types. PD-L1 is a critical immune regulatory molecule which can be expressed by tumor cells as a mechanism to escape immune surveillance. Assessment of tumor PD-L1 protein levels may have prognostic and/or therapeutic significance in some cancer patients. Identifying PD-L1 expression on tumor cells may help determine which patients will most benefit from anti-PD-1/PD-L1 therapy.